



Sofracort®

framycetin/gramicidin/dexamethasone Eye/Ear drops

The Issue: The framycetin/gramicidin/dexamethasone (5 mg-0.05 mg-0.5 mg/mL) eye/ear drops (Sofracort®) are on backorder by the sole manufacturer, Sanofi. NH has approximately 8 weeks of supply on hand in pharmacies.

Anticipated availability: end of July 2022

Practice Implications:

- Clinicians should be aware of this drug shortage and alternative formulary agents should sites start to run out of Sofracort®.

Potential Formulary Alternatives*:

Note: OPHTHALMIC suspensions CAN be administered in the ear but OTIC suspensions CANNOT be administered in the eye.

Brand Name*	Ingredients
Ophthalmic (eye or ear):	
Maxitrol® eye suspension	dexamethasone 0.1%, neomycin 3.5 mg/mL, polymyxin B sulfate 6000 IU/mL
Tobradex® eye suspension	tobramycin 0.3% and dexamethasone 0.1%
Tobradex® eye ointment	
Otic (ear only):	
Ciprodex® OTIC suspension	ciprofloxacin 0.3% and dexamethasone 0.1%

May 20, 2022 For the information of physicians, nurses, and pharmacists. PLEASE POST	Drug Shortage	✓	For further information contact: Medication Use Management Pharmacists: mumpharmacist@northernhealth.ca
	Drug Discontinuation		
	Medication Change		
	Best Practice		

*Alternatives are provided for clinician information and may not be appropriate for all clinical situations. The information provided does not replace clinical judgment.